Xavier RM - Search Results

1

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.

Taylor PC, Choy E, Baraliakos X, Szekanecz Z, Xavier RM, Isaacs JD, Strengholt S, Parmentier JM, Lippe R, Tanaka Y. Taylor PC, et al. Among authors: xavier rm. Rheumatology (Oxford). 2024 Feb 1;63(2):298-308. doi: 10.1093/rheumatology/kead448. Rheumatology (Oxford). 2024. PMID: 37624925 Free PMC article. Review.

2

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A. Choy E, et al. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Rheumatology (Oxford). 2018. PMID: 29244149 Free PMC article. Clinical Trial.

3

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A. Choy E, et al. Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. Rheumatology (Oxford). 2018. PMID: 29635639 Free PMC article. No abstract available.

4

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Pethö-Schramm A. Choy E, et al. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. Rheumatology (Oxford). 2019. PMID: 30649524 Free PMC article.

5

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.

Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Nash P, et al. Among authors: xavier r. Ann Rheum Dis. 2021 Jan;80(1):71-87. doi: 10.1136/annrheumdis-2020-218398. Epub 2020 Nov 6. Ann Rheum Dis. 2021. PMID: 33158881 Free PMC article.

6

Emerging protein kinase inhibitors for the treatment of rheumatoid arthritis.

Palominos PE, Lineburger IB, Xavier RM. Palominos PE, et al. Among authors: xavier rm. Expert Opin Emerg Drugs. 2021 Sep;26(3):303-321. doi: 10.1080/14728214.2021.1964472. Epub 2021 Aug 16. Expert Opin Emerg Drugs. 2021. PMID: 34365877 Review.

7

Efficacy of certolizumab pegol across baseline rheumatoid factor subgroups in patients with rheumatoid arthritis: Post-hoc analysis of clinical trials.

Tanaka Y, Takeuchi T, Haaland D, Hall S, Inanc N, Li Z, Xavier RM, Cara C, Tilt N, Taylor PC. Tanaka Y, et al. Among authors: xavier rm. Int J Rheum Dis. 2023 Jul;26(7):1248-1259. doi: 10.1111/1756-185X.14699. Epub 2023 May 17. Int J Rheum Dis. 2023. PMID: 37195063 Clinical Trial.

8

The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis.

Bredemeier M, Duarte ÂL, Pinheiro MM, Kahlow BS, Macieira JC, Ranza R, Miranda JR, Valim V, de Castro GR, Bértolo MB, Sauma MF, Fernandes V, Ribeiro AC, Teodoro RB, Brenol CV, Carvalho HM, Studart SA, Pinheiro GR, da Rocha LF Jr, de Lima HD, Pereira IA, Gazzeta MO, Kakehasi AM, Louzada P Jr, Hayata AL, Lupo CM, da Silveira IG, Kowalski SC, Titton DC, Chakr RM, Ranzolin A, Xavier RM, Laurindo IM. Bredemeier M, et al. Among authors: xavier rm. Rheumatology (Oxford). 2024 Feb 1;63(2):456-465. doi: 10.1093/rheumatology/kead232. Rheumatology (Oxford). 2024. PMID: 37216912

9

Effect of inflammatory activity and glucocorticoid [corrected] use on nutritional variables in patients with juvenile idiopathic arthritis.

Souza L, Machado SH, Bredemeier M, Brenol JC, Xavier RM. Souza L, et al. Among authors: xavier rm. J Rheumatol. 2006 Mar;33(3):601-8. J Rheumatol. 2006. PMID: 16511929

10

Differential CCR5Delta32 allelic frequencies in juvenile idiopathic arthritis subtypes: evidence for different regulatory roles of CCR5 in rheumatological diseases.

Scheibel I, Veit T, Neves AG, Souza L, Prezzi S, Machado S, Kohem C, Icarelli M, Xavier R, Brenol JC, Chies JA. Scheibel I, et al. Scand J Rheumatol. 2008 Jan-Feb;37(1):13-7. doi: 10.1080/03009740701631935. Scand J Rheumatol. 2008. PMID: 18189189

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

238 results

Search Page